T-cell engagers, bispecifics and CAR-T are changing myeloma care fast. Two HSANZ events in Sydney and Adelaide will help you get up to speed, and the Adelaide seminar is free, with a virtual option.
Gain practical insights into understanding and responding to the evolving needs of people living with CML, from diagnosis through treatment and beyond.
From 1 October 2026, Triptorelin 3.75mg (Diphereline®) will become available on the PBS for the treatment of a range of women’s health conditions, including breast cancer, endometriosis and uterine fibrosis.
As of 1 September 2026, nurse practitioners have been able to prescribe PBS-listed medicines for chronic myeloid leukaemia (CML) as a continuation of an existing therapy, where care is shared with a medical practitioner.
When is a rash more than just a rash? And what should you be looking for before a patient even tells you something has changed? Available exclusively to CNSA members, we encourage you to login and listen today!
